Posted by Michael Wonder on 13 Dec 2015
Canada's ERC rejects Novartis' Zykadia (ceritinib) for metastatic non-small cell lung cancer
3 December 2015 - The Committee was not confident of the net clinical benefit due to the limitations of the evidence from the available clinical trials.
For more details, go to: https://www.cadth.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_fn_rec.pdf
